Transplantation of parthenogenetic embryonic stem cells ameliorates cardiac dysfunction and remodelling after myocardial infarction

Cardiovascular Research

Volumn 97, Issue 2, 2013, Pages 208-218

  Liu, Yi ^a   Ye, Xiaoying ^a   Mao, Lina ^a,b   Cheng, Zhaokang ^a   Yao, Xinpeng ^a   Jia, Xiaohua ^a   Mao, Duo ^a   Ou, Lailiang ^a   Li, Zongjin ^a   Che, Yongzhe ^a   Liu, Na ^a   Steinhoff, Gustav ^c   Liu, Lin ^a   Kong, Deling ^a,b  

^a NANKAI UNIVERSITY   (China)

^b INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Embryonic stem cell; Myocardial infarction; Parthenogenetic stem cell; Stem cell therapy; Teratoma

Indexed keywords

ANGIOGENIC FACTOR; SODIUM CHLORIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FEMALE; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; PARTHENOGENESIS; PARTHENOGENETIC EMBRYONIC STEM CELL; PARTHENOGENETIC EMBRYONIC STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHAM PROCEDURE; SMOOTH MUSCLE FIBER; STAINING; STEM CELL TRANSPLANTATION; TERATOMA; TISSUE REGENERATION;

ANIMALS; CELL DIFFERENTIATION; COLLAGEN; EMBRYONIC STEM CELLS; FEMALE; LEUKOCYTES; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; PARTHENOGENESIS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84872548700     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs314     Document Type: Article

References (47)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486.
2. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451: 937-942.
3. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
4. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
5. Lim SY, Kim YS, Ahn Y, Jeong MH, Hong MH, Joo SY et al. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res 2006;70:530-542.
6. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-668.
7. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J et al. Bone marrowderived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 2004;10:494-501.
8. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685.
9. Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006;116:1865-1877.
10. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108:407-414.
11. Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C, Alekseev AE et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004;287:H471-H479.
12. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005;23:845-856.
13. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol 2011;50:327-332.
14. Zhang Y, Wang D, Chen M, Yang B, Zhang F, Cao K. Intramyocardial transplantation of undifferentiated rat induced pluripotent stem cells causes tumorigenesis in the heart. PLoS One 2011;6:e19012.
15. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471: 58-62.
16. Tongbiao Z, Zhen-Ning Z, Zhili R, Yang X. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:4.
17. Kim K, Lerou P, Yabuuchi A, Lengerke C, Ng K, West J et al. Histocompatible embryonic stem cells by parthenogenesis. Science 2007;315:482-486.
18. Kaufman MH, Robertson EJ, Handyside AH, Evans MJ. Establishment of pluripotential cell lines from haploid mouse embryos. J Embryol Exp Morphol 1983;73:249-261.
19. Cibelli JB, Grant KA, Chapman KB, Cunniff K,Worst T, Green HL et al. Parthenogenetic stem cells in nonhuman primates. Science 2002;295:819.
20. Mai Q, Yu Y, Li T, Wang L, Chen MJ, Huang SZ et al. Derivation of human embryonic stem cell lines from parthenogenetic blastocysts. Cell Res 2007;17:1008-1019.
21. Allen ND, Barton SC, Hilton K, Norris ML, Surani MA. A functional analysis of imprinting in parthenogenetic embryonic stem cells. Development 1994;120:1473-1482.
22. Chen Z, Liu Z, Huang J, Amano T, Li C, Cao S et al. Birth of parthenote mice directly from parthenogenetic embryonic stem cells. Stem Cells 2009;27:2136-2145.
23. Liu Z, Hu Z, Pan X, Li M, Togun TA, Tuck D et al. Germline competency of parthenogenetic embryonic stem cells from immature oocytes of adult mouse ovary. Hum Mol Genet 2011;20:1339-1352.
24. Jiang H, Sun B, Wang W, Zhang Z, Gao F, Shi G et al. Activation of paternally expressed imprinted genes in newly derived germline-competent mouse parthenogenetic embryonic stem cell lines. Cell Res 2007;17:792-803.
25. Koh CJ, Delo DM, Lee JW, Siddiqui MM, Lanza RP, Soker S et al. Parthenogenesisderived multipotent stem cells adapted for tissue engineering applications. Methods 2009;47:90-97.
26. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009;27:743-745.
27. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571-579.
28. Cheng Z, Ou L, Liu Y, Liu X, Li F, Sun B et al. Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion. Cardiovasc Res 2008;80:425-434.
29. Zhou B, Honor LB, He H, Ma Q, Oh JH, Butterfield C et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest 2011;121: 1894-1904.
30. Mair J, Dienstl F, Puschendorf B. Cardiac troponin T in the diagnosis of myocardial injury. Crit Rev Clin Lab Sci 1992;29:31-57.
31. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
32. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009;81:457-464.
33. Kolettis TM. Arrhythmogenesis after cell transplantation post-myocardial infarction. Four burning questions-and some answers. Cardiovasc Res 2006;69:299-301.
34. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003;92:139-150.
35. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999;44:232-241.
36. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 2005;96:110-118.
37. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114: 763-776.
38. Crisostomo PR, Abarbanell AM, Wang M, Lahm T, Wang Y, Meldrum DR. Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. Am J Physiol Heart Circ Physiol 2008;295:H1726-H1735.
39. Cao Y, Hong A, Schulten H, Post MJ. Update on therapeutic neovascularization. Cardiovasc Res 2005;65:639-648.
40. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742.
41. Li L, Baroja ML, Majumdar A, Chadwick K, Rouleau A, Gallacher L et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004;22: 448-456.
42. Min JY, Yang Y, Converso KL, Liu L, Huang Q, Morgan JP et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol 2002; 92:288-296.
43. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 2007;21:1345-1357.
44. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25: 1015-1024.
45. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007;204:405-420.
46. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999;253:63-77.
47. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-776.